as a key obstacle to expanding the donor pool. However, despite clinical importance, mechanisms that account for liver IRI are partially understood, and there are no effective strategies to combat IRI in humans. 1 Relaxin, a group of low-molecular-weight peptide hormones of the insulin-growth factor family, consists of 7 members, with relaxin-2 (RLX-2) accounting for most of the biological effects in humans and animals. 2 Originally isolated from ovary and named for its ability to "relax" pubic symphysis during pregnancy, 3 relaxin plays a role in hemodynamic change, such as decreasing systemic vascular resistance, increasing cardiac output, and improving global arterial compliance. 4 Experiments demonstrating cytoprotective, 5 antiinflammatory 6 and antifibrotic 7 functions, possibly due to antioxidant effects, underscore the increasing interest in RLX-2 as a pharmacotherapeutic agent. Indeed, a recent phase III randomized clinical trial showed the efficacy, safety, and tolerability of Serelaxin (SER, recombinant human relaxin-2) in patients with acute heart failure. 8 By binding with high affinity to cognate receptor relaxin family peptide receptor 1 (RXFP1), the majority of RLX-2-related signal transduction involves the RXFP1 molecule. 9 RXPF1 is expressed in reproductive tissues, heart, kidney, lung, and brain, 10 while protective effects of RLX-2 induction were described in heart, 2 kidney, 11 and lung 12 IRI models. Although barely detectable in normal rat liver, RXFP1 is expressed predominantly in fibrotic lesion after chronic carbon-tetrachloride treatment. 13 The mechanisms and putative clinical relevance of apparent RLX-2 protection seen in ex vivo isolated rat livers 14 remain to be elucidated.
Notch1 is a highly conserved transmembrane receptor involved in cell fate decision, proliferation, differentiation and regeneration. 15 Upon ligand binding, the Notch intracellular domain (NICD)
is released by proteolytic cleavage operated by the γ-secretase complex, and translocates into the nucleus followed by the activation of Notch1 target genes, including hairy and enhancer of split 1 (Hes1).
16
Disruption of Notch1 transcription factor RBP-J increased cell apoptosis/necrosis and inflammatory response leading to aggravated liver IRI. 17 We have shown that myeloid-specific Notch1 deficiency augmented macrophage activation and hepatocellular damage in a mouse warm IRI model. 18 The 
| MATERIAL S AND ME THODS

| Animals
C57BL/6 mice at 6-8 weeks of age were used (Jackson Laboratory, Bar
Harbor, ME). Animals were housed in a UCLA animal facility under specific pathogen-free conditions and received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" (NIH publication 86-23 revised 1985). All studies were reviewed and approved by the UCLA Animal Research Committee.
| Reagents
Serelaxin (SER; recombinant form of human relaxin-2, RLX030) was provided by Novartis International AG (East Hanover, NJ).
Lipopolysaccharides (LPS) and IL4 were obtained from Sigma Aldrich (St. Louis, MO).
| Mouse liver transplantation
We used an established mouse model of ex vivo hepatic cold storage and OLT. 22 To mimic the "marginal" human OLT setting, donor livers were stored in University of Wisconsin (UW) solution at 4°C for 18 hours prior to transplantation into syngeneic mice. Animals were treated intravenously with SER (5 μg/kg) or Ringer's lactate solution (control) at the time of reperfusion. Optimal dose of SER was determined in a preliminary experiment comparing the effects of 0/1/3/5/10 μg/kg given at the time of reperfusion (n = 2/group, data not shown). Liver and serum samples were collected at 6 hours, the peak of hepatocellular damage in this model.
Separate groups of OLT recipients were monitored for 14-day survival.
The sham group underwent the same procedures except for OLT.
| Hepatocellular function assay
Serum alanine aminotransferase (sALT) and aspartate aminotransferase (sAST) levels were measured with Infinity ALT and AST Liquid Stable Reagent (Thermo Scientific, Rockford, IL) and validated with
ValidateGC3 (Maine Standards Company, LLC, ME).
| Liver histology and IRI grading
Formalin-fixed paraffin-embedded liver sections (5 μm) were stained with hematoxylin and eosin (H&E). The severity of IRI was graded using Suzuki's criteria. 
| Immunohistochemistry
The expression of RXFP1 (liver and heart) was examined using rabbit anti-RXFP1 Ab (Santa Cruz Biotechnology, Santa Cruz, CA).
Immunostaining signals were visualized with a labeled polymer in the EnVision+ system horseradish-peroxidase kit (Dako, Carpinteria, CA).
Liver-infiltrating neutrophils and macrophages were detected with rat 
| Cell isolations and in vitro cultures
Femurs and tibias were removed from wild-type (WT) mice, and bone marrow-derived macrophages (BMDMs) were generated, as described. 22 In some experiments, cells pretreated with SER (5 μg/mL, 24 hours) were stimulated with LPS (100 ng/mL, 6 hours) or IL4
(10 ng/mL, 24 hours).
| Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) analysis
RNA was extracted from livers or cell samples using RNAse Mini Kit (Table S1 ). The expression of the target gene was normalized to the housekeeping HPRT or β2M.
| Western blot assay
Proteins were extracted from liver or cell samples, followed by concentration measurement (BCA Protein Assay Kit, Thermo Scientific).
Equal amount of protein was electrophoresed, blotted, and incubated with primary Ab and secondary HRP-conjugated Ab, and developed.
Primary Ab detecting NICD, pIκBα (Ser32), cleaved caspase-3, glucocorticoid receptor (GR), β-actin (Cell Signaling Technology, Danvers, MA), Hes1, RXFP1 (Santa Cruz Biotechnology), and CD206 (R&D Systems, Minneapolis, MN) were used.
| Clinical liver transplantation study
Twenty-one adult OLT recipients recruited between May 2013 and August 2015 received routine standard of care and immunosuppressive therapy, as specified by UCLA liver transplant protocols. 23 Study data were managed using REDCap electronic data capture tools.
Recipient blood was collected prior to the transplant and at postoperative day 1 (POD1). Liver function was evaluated by sALT/sAST.
Posttransplantation biopsy (Bx) samples were collected from the left liver lobe 2 hours after portal reperfusion (prior to the abdominal closure) followed by western blot analyses. To compare target protein expression in multiple human OLT samples, densitometry quantification was conducted using a reference sample and normalization with β-actin, as reported. 23 
| Statistical analysis
In mouse experiments, group comparisons were performed using a Student t-test. For human data, continuous values were analyzed by
Mann-Whitney U test and categorical variables by Fisher's exact test.
The cumulative survival rate was analyzed by the Kaplan-Meier method, and differences between groups were compared using a log-rank test.
JMP for Windows 8.0 (SAS Institute, Cary, NC) was used for statistical analyses. A P-value of <.05 was considered statistically significant.
| RE SULTS
| SER ameliorates hepatic IRI and improves OLT survival
We first aimed to determine the efficacy of SER treatment in mouse 
| Marginal hepatic RXFP1 expression in OLT with/without SER treatment
Having shown the hepatoprotective effect of SER treatment in IRstressed OLT, we next assessed RXFP1 (cognate receptor of SER) expression, aiming to gain insight into underlying SER cytoprotection.
Consistent with previous reports, 13 unlike in normal murine heart (positive control), RXFP1 was undetectable by immunohistology in sham-operated livers ( Figure S1A ). Neither OLT nor SER treatment affected hepatic RXFP1 expression-data confirmed by western blots ( Figure S1B ). Moreover, SER treatment failed to enhance RXFP1 levels in IR-stressed OLT. Hence, it is unlikely that RXFP1
signaling is essential in SER hepatoprotection.
| SER mitigates leukocyte infiltration in IRstressed OLT
Because cytokine/chemokine-producing leukocytes in OLT accelerate IR-damage, we next evaluated the SER effect on neutrophil (Ly6G) and macrophage (CD11b) infiltration (n = 5/group). As shown in Figure 2A ,B, decreased numbers of Ly6G+ and CD11b+ cells were observed in SER treated as compared with control OLT (Ly6G: control-OLT = 44.4 ± 3.5 vs SER-OLT = 27.2 ± 4.8/HPF; P = .001; and CD11b:
control-OLT = 39.6 ± 2.2 vs SER-OLT = 26.6 ± 5.7/HPF; P = .002).
| SER suppresses proinflammatory IR-signature and induces Notch1 signaling in OLT
Because our recent study has identified the regulatory function of Notch1 for innate immune activation in liver IRI, 18 we next asked whether SER may promote Notch1 signaling in OLT. Indeed, as shown in Figure 2C , SER treatment was accompanied by upregulation of NICD and Hes1 (one of downstream Notch1 target genes).
In addition, SER decreased pIκBα expression ( Figure 2C ), depressed mRNA levels of pro-inflammatory MCP1, IL1β, CXCL1, CXCL2, and CXCL10, and increased mRNA levels of antiinflammatory Arg1 and IL10 ( Figure 2D ). Consistent with Figure 1A ,B findings, SER treat- 
| SER induces Notch1 signaling and inhibits LPSstimulated macrophage activation in vitro
Because macrophages play a key role in innate immune activation SER enhanced Notch1 signaling (NICD and Hes1, Figure 3A) ; decreased pIκBα protein expression ( Figure 3A) ; suppressed proinflammatory gene program (MCP1, IL1β, CXCL1, CXCL2, and CXCL10); and increased immunoregulatory Arg1 signaling in LPSstimulated BMDM ( Figure 3B ). As shown in Figure S2 , and increasing dose of SER treatment upregulated NICD and CD206 while decreasing pIκBα levels in cultured BMDM. Of note, the expression of RXFP1 and glucocorticoid receptor (or GR, another SER receptor) remained unchanged, implying the importance of Notch1 signaling in macrophage regulation.
| SER enhances antiinflammatory gene expression in IL4-stimulated macrophage cultures
We next examined whether SER may affect antiinflammatory gene programs in vitro. Consistent with Figures 2C, 3A data, SER increased NICD and Hes1 expression in IL4-stimulated BMDMs ( Figure 3C ). In parallel, SER adjunct enhanced mRNA levels coding for antiinflammatory Arg1, CD163, and CCL24 ( Figure 3D ). These findings, consistent with our studies on the critical role of Notch1 in macrophage immunoregulation, 18 imply Notch1 in SER-mediated macrophage regulation.
| Increased NICD expression correlates with attenuated liver damage in human OLT
Having shown the regulatory function of Notch1 in SER-mediated hepatoprotection in mouse OLT, we next aimed to determine the clinical relevance of Notch1 signaling in human OLT. 
| D ISCUSS I ON
A recent phase III randomized clinical trial in a cohort of 1161 patients with acute heart failure demonstrated that SER treatment was associated with an improvement of patients' symptoms and significant To the best of our knowledge, our study is the first to document the beneficial impact of Notch1 induction in liver transplant patients.
Indeed, high-NICD levels in hepatic Bx at the time of reperfusion correlated with lower sALT levels at POD1 ( Figure 4B , left panel), with no correlation between NICD expression and donor/recipient baseline parameters (Table S2 ). As our failure to detect significant differences in sAST levels ( Figure 4B right panel) , post-OLT hospital stay, and post-OLT patient survival might be due to a limited patient cohort (n = 21), future studies with a larger number of OLT recipients are warranted.
RXFP1 was barely detectable in mouse livers, and neither OLT nor SER treatment altered its marginal hepatic expression ( Figure   S1A ,B). Indeed, Fallowfield reported that no RXPF1 protein was detected in naive human or rat livers, whereas RXFP1 became detectable on stellate cells/myofibroblasts and sinusoidal endothelial cells in fibrotic livers. 13 However, despite minimal RXFP1 expression in by RXFP1-PI3K-Akt-endothelial nitric oxide synthase (eNOS) axis on artery and endothelial cells, whereas relaxin dilated sinusoid in unstressed rat liver via an nitric oxide (NO)-dependent manner. 28 Therefore, endothelial RXFP1-signal induction followed by sinusoid dilatation might be a part of the hepatoprotective SER mechanism in OLT. Studies using RXFP1 knockout mice or chemically modified RXFP1-inactive relaxin 29 are needed to substantiate the involvement of RXFP1 in SER-mediated hepatoprotection.
Notch1 signal deficiency by genetic RBP-J disruption decreased manganese superoxide dismutase while increasing ROS and hepatocyte apoptosis. 17 In line with this finding, SER-mediated Notch1 upregulation may exert direct cytoprotection in hepatocytes. On the other hand, SER-primed hepatocyte GR signaling may also promote an anti-apoptotic pathway. 30 Indeed, SER cytoprotection was abolished after glucocorticoid receptor (GR) silencing using small interfering RNA (siRNA) in mouse primary hepatocyte cultures, indicating dominant contribution of GR in hepatocyte protection by SER.
In conclusion, our preclinical study documents the efficacy of with acute heart failure, 8 our translational study supports the rationale for using SER in clinical liver transplantation. 
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